Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Zhekang Jin"'
Autor:
Yue Liu, Qian Xiao, Jinjie He, Hanguang Hu, Jinlin Du, Yuping Zhu, Jiaqi Chen, Zhuo Liu, Jianping Wang, Lifeng Sun, Dong Xu, Jun Li, Xiujun Liao, Jianwei Wang, Yibo Cai, Cheng Cai, Zhekang Jin, Liuhong Wang, Ying Yuan, Kefeng Ding
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-10 (2022)
Abstract Background Anlotinib, an oral small molecule tyrosine kinase inhibitor targeting VEGFR 1/2/3, FGFR 1-4, PDGFR a/β, and c-kit, had demonstrated prolonged progression-free survival (PFS) in refractory metastatic colorectal cancer (mCRC). This
Externí odkaz:
https://doaj.org/article/546bcd30f51940458ee15c2d1ec70809
Autor:
Ke-Feng Ding, Yue Liu, Qian Xiao, Jinjie He, Hanguang Hu, Jinlin Du, Yuping Zhu, Jiaqi Chen, Zhuo Liu, Jianping Wang, Lifeng Sun, Dong Xu, Jun Li, Xiujun Liao, Jianwei Wang, Yibo Cai, Cheng Cai, Zhekang Jin, Ying Yuan
Publikováno v:
Journal of Clinical Oncology. 41:138-138
138 Background: Anlotinib is an oral multi-target tyrosine kinase inhibitor, mainly targeting VEGFR1-3, FGFR 1-4, PDGFR a/b and c-kit. Previous trial had demonstrated that anlotinib monotherapy was effective and safe in advanced colorectal cancer. AL
Autor:
Yue Liu, Qian Xiao, Jinjie He, Hanguang Hu, Jinlin Du, Yuping Zhu, Jiaqi Chen, Zhuo Liu, Jianping Wang, Lifeng Sun, Dong Xu, Jun Li, Xiujun Liao, Jianwei Wang, Yibo Cai, Cheng Cai, Zhekang Jin, Liuhong Wang, Ying Yuan, Kefeng Ding
Publikováno v:
BMC medicine. 20(1)
Background Anlotinib, an oral small molecule tyrosine kinase inhibitor targeting VEGFR 1/2/3, FGFR 1-4, PDGFR a/β, and c-kit, had demonstrated prolonged progression-free survival (PFS) in refractory metastatic colorectal cancer (mCRC). This multicen
Autor:
Zhuo Liu, Cheng Cai, Qian Xiao, Yibo Cai, Hongfeng Cao, Lifeng Sun, Yue Liu, Kefeng Ding, Zhekang Jin, Ying Yuan, Jinlin Du, Liao Xiujun, Jianping Wang, Dong Xu, Jinjie He, Yuping Zhu, Jun Li, Jianwei Wang
Publikováno v:
Journal of Clinical Oncology. 39:e15564-e15564
e15564 Background: Antiangiogenic therapy plus chemotherapy is one of the standard treatments in mCRC. Anlotinib, an oral small multi-targeted tyrosine kinase inhibitor targeting VEGFR 1/2/3, FGFR 1-4, PDGFR α/β and c-kit, has demonstrated prolonge